In recent years, it has been nearly impossible to open a news app or scroll through social media without seeing a headline about GLP-1 agonists. Often framed strictly through the lens of weight loss, these medications have sparked a global conversation about body image and the "pills vs. pens" debate. However, focusing solely on the scale does a disservice to the true scientific breakthrough these molecules represent.

We are currently witnessing a shift in the medical community where GLP-1s are being redefined. They are no longer just "weight loss drugs"—they are powerful metabolic regulators with the potential to treat a spectrum of chronic conditions, from heart disease to liver dysfunction.

At Science 37, we believe that understanding the systemic impact of these therapies is key to unlocking better long-term wellness for millions of people. As research expands into these new frontiers, the role of at-home clinical trials is becoming more vital than ever in proving how these treatments can protect our most vital organs.

The Science of GLP-1: A Multi-Organ Master Regulator

Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in the gut in response to food. While its most famous role is stimulating insulin secretion, its influence stretches far beyond the pancreas. To understand why GLP-1 agonists are being studied for so many different diseases, we have to look at how they interact with different organ systems.

The Brain and Appetite Control In the brain, GLP-1 receptors are located in areas that regulate appetite and reward. By mimicking the natural hormone, these medications signal a feeling of satiety, or fullness, much earlier than usual. But beyond just "feeling full," researchers are investigating how these signals might reduce systemic inflammation in the brain, potentially offering neuroprotective benefits that go beyond metabolic health.

The Heart and Vascular System Perhaps the most exciting frontier for GLP-1 agonists is heart health. These receptors are present in the heart muscle and the lining of blood vessels. Clinical data suggests that GLP-1s can help reduce blood pressure, improve lipid profiles, and decrease the risk of major adverse cardiovascular events (MACE) like heart attacks and strokes. By improving insulin sensitivity and reducing the "pro-inflammatory" state of the body, these drugs help protect the entire cardiovascular system.

The Liver and MASH/NASH Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH, is a leading cause of liver transplants. It involves the buildup of fat in the liver, leading to inflammation and scarring. GLP-1 agonists appear to help the liver by reducing fat accumulation and dampening the inflammatory response. This makes them a primary candidate in Type 2 diabetes research and liver-specific clinical trials seeking to reverse the damage caused by fatty liver disease.

By the Numbers: The Rising Tide of Metabolic Disorders

The urgency of this research is underscored by the current health landscape in the United States. Metabolic disorders are not isolated incidents; they are part of an interconnected web of chronic disease management that affects a staggering portion of the population.

Type 2 Diabetes: According to the CDC, over 38 million Americans have diabetes, and roughly 90-95% of them have Type 2.

Obesity: The adult obesity rate in the U.S. stands at approximately 42%, a condition that significantly increases the risk for heart disease and chronic kidney disease.

Heart Disease: Cardiovascular disease remains the leading cause of death globally, with metabolic dysfunction acting as a primary driver for arterial plaque buildup.

MASH/NASH: It is estimated that nearly 25% of adults worldwide have some form of non-alcoholic fatty liver disease, many of whom remain undiagnosed until the damage is advanced.

These statistics represent more than just data; they represent a growing need for accessible, effective medical interventions. As these conditions often cluster together—a phenomenon known as metabolic syndrome—the need for a "systemic" treatment like GLP-1 agonists becomes clear.

The Evolution of Participation: Remote Clinical Trials for Busy Lives

Despite the clear need for new treatments, many people who would benefit most from participating in clinical trials for weight loss or metabolic health are the ones least likely to have time for them. Busy professionals, parents, and those managing the fatigue associated with chronic disease often find the logistics of traditional trials—frequent travel and hours in waiting rooms—to be an insurmountable barrier.

This is where the Science 37 model of decentralized research changes the equation. By utilizing at-home clinical trials, we remove the friction of participation.

How Remote Participation Works for Metabolic Research:

Telehealth Consultations: Instead of driving to a clinic, you meet with world-class investigators via secure video calls from your office or living room.

Wearable Technology: Devices can track your activity, heart rate, and even glucose levels in real-time, providing more accurate data than a single snapshot taken in a doctor's office.

Direct-to-Door Supplies: Investigational medications and testing kits are delivered directly to your home, ensuring you never miss a dose or a data point.

Local Nursing Support: If a physical check-up is required, a mobile nurse can come to you, meeting you at a time and place that fits your life.

This approach doesn't just make life easier; it improves the science. When people can participate from their natural environment, researchers get a clearer picture of how a medication works in the "real world," leading to safer and more effective treatments.

Do’s and Don’ts for Managing Metabolic Health

While we wait for the next generation of GLP-1 applications to be approved, there are steps you can take today to support your metabolic health.

Do:

Prioritize Lean Protein: Protein helps stabilize blood sugar and supports muscle mass, which is vital when using metabolic treatments.

Stay Hydrated: GLP-1s can affect your thirst signals; ensure you are drinking water consistently throughout the day.

Monitor Your Stats: Keep a log of your blood pressure and energy levels to share with your healthcare provider.

Don’t:

Skip Meals: Even if you don't feel hungry, your body needs consistent fuel to maintain its basal metabolic rate.

Ignore Muscle Health: Incorporate resistance training to ensure that weight loss comes from fat, not muscle tissue.

Self-Prescribe: Always work through a regulated clinical study or with a licensed provider to ensure the medication is right for your profile.

Frequently Asked Questions

What is the difference between various GLP-1s? While many medications use similar active ingredients (like semaglutide), they are FDA-approved for different primary uses—some for Type 2 diabetes and others specifically for chronic weight management. Newer medications are "dual agonists" that target multiple hormone receptors for greater metabolic impact.

How long do I need to be in a clinical trial? Trial lengths vary. Some metabolic health trials last a few months, while others looking at long-term heart health may last a year or more. The "at-home" model makes these longer durations much easier to manage.

Are there side effects to GLP-1 agonists? The most common side effects are gastrointestinal, such as nausea, which usually improve as the body adjusts. Clinical trials are essential for monitoring these effects and finding optimal dosing schedules.

Will my insurance cover these treatments? Insurance coverage for GLP-1s is currently in flux. However, one of the benefits of participating in a Science 37 clinical trial is that the investigational medication and all study-related care are provided at no cost to the participant.

A New Chapter in Wellness

The story of GLP-1s is still being written. We are moving toward a future where "metabolic health" is seen as the foundation of all wellness—where protecting the heart, liver, and kidneys is as standard as checking a pulse.

By participating in clinical research, you are helping to prove that these medications can save lives by preventing heart attacks and reversing liver disease. If you are ready to take control of your metabolic health and contribute to the next great leap in medical science, Science 37 is here to bridge the gap. Explore our active clinical trials today and discover how you can access the future of metabolic care from the comfort of your own home.

For many families living with Lennox-Gastaut Syndrome (LGS), the daily focus is often—understandably—on seizure control. When you are managing multiple types of seizures, including dangerous drop seizures that can lead to injury, the physical safety of your loved one is the immediate priority. However, LGS is a multifaceted condition that extends far beyond the electrical storms in the brain.

To truly understand LGS, we must look at the "hidden" challenges: the cognitive impairment and behavioral health issues that significantly impact the quality of life for both the patient and the caregiver. As medical advancements continue to evolve, our approach to research is also changing, shifting toward a more inclusive model that addresses the whole person, not just their seizure count.

The Signature of LGS: The Slow Spike-Wave Pattern

One of the defining characteristics of Lennox-Gastaut Syndrome is a specific pattern found on an electroencephalogram (EEG) known as the "slow spike-and-wave." While a typical EEG shows rapid electrical communication between brain cells, the LGS brain often displays a rhythmic, slower electrical discharge (usually less than 2.5 Hertz).

What does this mean for daily life? These slow-wave discharges occur not just during a seizure, but often while the patient is awake and appearing "stable." This constant background noise in the brain acts like static on a radio, making it difficult for the brain to process information, learn new skills, or retain memories. This is a primary driver of the cognitive impairment seen in LGS. By understanding this electrical signature, researchers are better equipped to develop therapies that don't just stop a physical convulsion, but also help "clear the static" to support better cognitive function.

Debunking Myths: LGS is More Than Just Seizures

There is a common misconception that if you can stop the seizures, you "fix" the LGS. Unfortunately, the reality is more complex. Understanding the truth behind these myths is essential for finding the right care and research opportunities.

• Myth: Seizure freedom equals cognitive recovery. Fact: While reducing seizure frequency is vital, the underlying encephalopathy (brain dysfunction) of LGS often persists. Modern pediatric epilepsy research is now looking at "neurodevelopmental" outcomes—how we can support brain growth and learning alongside seizure management.
• Myth: Behavioral issues are just a "side effect" of medication. Fact: While some anti-seizure medications can impact mood, many behavioral health challenges—such as hyperactivity, aggression, or autism-spectrum traits—are actually part of the LGS clinical picture itself.
• Myth: Once a child reaches adulthood, LGS "levels off." Fact: LGS is a lifelong journey. As the brain ages, the types of seizures and cognitive needs may shift, which is why continued participation in clinical trials across all ages is so important.

The Power of the Natural Environment in Research

Historically, participating in LGS clinical trials required frequent, stressful visits to specialized epilepsy centers. For a patient who may struggle with sensory processing or the anxiety of new environments, these trips can trigger behavioral outbursts or even more frequent drop seizures.

This is where decentralized research is making a massive difference. Through at-home study participation, Science 37 allows families to contribute to medical science from the safety and comfort of their living rooms.

Why the home environment matters for LGS data:

1. Accurate EEG Monitoring: Portable, wearable EEG technology allows doctors to see the slow spike-wave patterns during a patient's actual daily routine, rather than in a sterile hospital bed.
2. Real-World Behavior: Caregivers can report on behavioral health and cognitive milestones in real-time using mobile apps, capturing the "good days and bad days" more accurately than a once-a-month office visit allows.
3. Safety First: For those prone to drop seizures, staying at home eliminates the risks associated with long-distance travel and navigating unfamiliar public spaces.

Improving Quality of Life Through Inclusive Research

The goal of modern LGS clinical trials is no longer just "seizure reduction." We are looking for treatments that help a child stay more alert during the day, improve their ability to communicate their needs, and reduce the behavioral hurdles that make social interaction difficult.

By choosing to participate in a virtual clinical trial, you are helping researchers understand the full spectrum of Lennox-Gastaut Syndrome. You are providing the data needed to create a future where treatments are as diverse as the needs of the LGS community.

Frequently Asked Questions

How do drop seizures affect long-term cognitive health? Drop seizures (atonic seizures) cause a sudden loss of muscle tone. While the seizure itself is brief, the frequent "resets" to the brain's electrical state and the constant risk of head trauma can contribute to further cognitive delays and an increased fear of physical activity.

What behavioral health support is available for LGS families? In addition to medication, many families find success with Applied Behavior Analysis (ABA) therapy, sensory integration, and specialized educational plans. Clinical research is also looking into how non-sedating therapies can help manage irritability without causing further grogginess.

Can my child join a trial if they are non-verbal? Absolutely. In fact, it is vital that non-verbal patients are represented in research. Decentralized trials use caregiver-reported outcomes and objective data from wearable devices to ensure that every patient’s experience is captured, regardless of their ability to speak.

What is the "slow" in slow spike-wave? The "slow" refers to the frequency of the electrical pulses. In LGS, these pulses happen at a rate that interferes with the brain's ability to "keep up" with incoming information, leading to what many describe as a cognitive "fog."

A Partner in Your LGS Journey

At Science 37, we believe that research should fit your life—not the other way around. Managing Lennox-Gastaut Syndrome is a full-time job, and your contribution to science shouldn't make that job harder. By bringing the trial to you, we ensure that the most vulnerable patients have a seat at the table in developing the next generation of epilepsy care.

If you are ready to explore a different kind of research experience—one that values the cognitive and behavioral health of your loved one as much as you do—view our current LGS study opportunities today.

For families living with Dravet syndrome, the journey often begins with a terrifying milestone: a prolonged, fever-related seizure in the first year of life. What starts as a frightening "first" quickly evolves into a complex, lifelong management of treatment resistant epilepsy. However, we are entering a transformative era in rare epilepsy research. We are moving away from broad-spectrum treatments and toward precision medicine—a shift that promises to address the underlying cause of the condition rather than just the symptoms.

At Science 37, we recognize that for a child with Dravet syndrome, a trip to a distant research hospital isn't just a commute; it’s a high-stakes logistical challenge that can trigger the very seizure clusters families work so hard to avoid. That is why the future of Dravet care isn't just about better science—it’s about better access through at-home clinical trials.

Understanding the "Why": The SCN1A Mutation

To understand the evolution of care, we must look at the biological blueprint of the condition. Approximately 80% of those diagnosed with Dravet syndrome have a mutation in the SCN1A gene. This gene is responsible for creating a protein that forms a "sodium channel" in the brain.

Think of these channels as the gatekeepers of electrical signals. In a typical brain, these gates open and close to keep electrical activity balanced. With an SCN1A mutation, these gates don't function correctly, specifically within inhibitory neurons—the cells meant to "calm" brain activity. When the "brakes" of the brain fail, the result is over-excitation, leading to frequent and often prolonged seizures.

Because this is a genetic issue, researchers are now focusing on precision medicine. This means developing therapies that specifically target the SCN1A pathway or attempt to restore the function of those sodium channels. It is a shift from "stopping a seizure" to "fixing the signaling error" at its source.

The Burden of Traditional Research

In the past, participating in rare epilepsy research meant traveling to specialized centers, often located hundreds of miles away. For a child with Dravet syndrome, this presents significant risks:

• Travel Stress: Changes in routine, sleep deprivation, and the physical strain of travel are well-known triggers for seizure clusters.
• Environmental Triggers: Exposure to fluctuating temperatures in airports or cars can be dangerous for heat-sensitive patients.
• Caregiver Strain: Balancing work and the needs of other siblings while traveling for weeks at a time creates an immense burden on caregiver support systems.

These barriers often meant that only a small, specific group of people could participate in research. This is where decentralized clinical trials are changing the landscape. By bringing the study to the patient, we can collect more accurate, "real-world" data while keeping the child in a safe, controlled environment.

Managing the Environment: Do’s and Don’ts of Heat Sensitivity

One of the most unique aspects of Dravet syndrome is temperature sensitivity. A slight rise in core body temperature—whether from a fever, physical activity, or a warm day—can trigger a seizure. As we look toward future treatments, daily management remains the cornerstone of care.

Do:

• Use Cooling Gear: Utilize cooling vests, neck wraps, or damp towels during outdoor activities or transit.
• Pre-treat Fevers: Work with your neurology team to establish a protocol for aggressive fever management at the first sign of illness.
• Monitor Ambient Temp: Keep indoor environments consistently cool, especially during sleep, as night seizures are common.
• Hydrate Strategically: Encourage cool fluids frequently to help regulate internal temperature.

Don’t:

• Rely on "Wait and See": Because seizures in Dravet can quickly become status epilepticus (prolonged seizures), don't hesitate to use rescue medications as prescribed.
• Assume "Warm" is "Safe": It doesn't take a "high" fever to trigger an event; even a minor elevation can be a catalyst.
• Overlook Bath Temperature: Always test bath water to ensure it is lukewarm or cool, never hot.

Why Your Participation Matters

The progress we’ve seen in neurological disorders over the last decade is a direct result of families choosing to participate in clinical trials for kids. However, we know that for your family to participate, the process must be patient-centric.

Through Science 37, at-home clinical trials allow for virtual visits with specialists, local nursing support, and wearable technology that monitors activity without the need for a hospital stay. This model ensures that rare epilepsy research is inclusive, reaching families regardless of their zip code.

By joining a study, you aren't just seeking a new option for your child; you are helping to refine the precision medicine that will define the next generation of Dravet syndrome care.

Frequently Asked Questions

What makes Dravet syndrome different from other types of epilepsy? Dravet syndrome usually begins in the first year of life with prolonged seizures, often triggered by fever. Unlike many other epilepsies, it is highly resistant to standard medications and is frequently associated with the SCN1A gene mutation, leading to developmental and movement challenges over time.

Can my child participate in a trial if we don't live near a major city? Yes. Science 37 specializes in decentralized research, which means many of the requirements of a study—such as check-ins and data monitoring—can be done from your home, making clinical trials accessible to families everywhere.

Is precision medicine only for people with the SCN1A mutation? While many current "targeted" therapies focus on the SCN1A mutation, research is also expanding into other pathways that affect how neurons communicate. Every trial contributes to a broader understanding of how to stabilize the brain's electrical activity.

How does at-home research keep my child safe? At-home trials reduce the stress and environmental triggers associated with travel. Participants are monitored closely by a mobile clinical team and use telehealth to stay in constant contact with investigators, ensuring that the child’s safety and the family's comfort are the top priorities.

Shaping the Future of Rare Disease Care

The evolution of Dravet syndrome care is moving fast. We are no longer just guessing which medications might work; we are using the SCN1A mutation as a roadmap to find answers. If you are interested in seeing how your family can contribute to these new frontiers in research, we invite you to explore our current offerings.

Together, we can move closer to a world where seizure clusters are a thing of the past and precision medicine is the standard for every child. Visit the Science 37 platform today to learn more about our current clinical trials and how you can get involved from the comfort of your own home.

If you have followed health news recently, you have undoubtedly heard about the "weight loss revolution" driven by medications like Ozempic, Wegovy, and Zepbound. These drugs, known as GLP-1 receptor agonists, have changed the game for type 2 diabetes management and long term weight management.

However, for many patients, there is a significant hurdle: the needle.

While weekly injections have become the standard, "needle fatigue" is real. The next frontier in metabolic health is moving away from the pen and toward the pill bottle. But can a daily tablet really compete with the potent effects of a weekly shot?

Here is a breakdown of oral GLP-1 vs injectable treatments, and what you need to know about the race to create a needle-free future.

The Science: Same Hormone, Different Delivery

Whether you take it as a shot or a pill, the active ingredient works the same way. GLP-1 (glucagon-like peptide-1) is a hormone that signals your brain that you are full, slows down gastric emptying, and helps regulate blood sugar.

The difference lies in how it gets into your system.

• Injectables (Pens): Deliver the medication directly into the fatty tissue, bypassing the stomach completely. This allows for high absorption (bioavailability).
• Orals (Pills): Must survive the harsh, acidic environment of the stomach. This is the biggest scientific challenge. Peptides are fragile; without special technology, your stomach would digest the medicine like food before it ever entered your bloodstream.

Comparing Efficacy: Rybelsus vs. Ozempic

Currently, the only FDA-approved oral GLP-1 for type 2 diabetes is Rybelsus (oral semaglutide).

• The Shot (Ozempic/Wegovy): Proven to lead to significant weight loss (15% or more in some trials) and robust blood sugar control.
• The Pill (Rybelsus): In its current approved doses, it is highly effective for blood sugar but generally produces less weight loss than the high-dose injectables.

However, this gap is closing. New clinical trials are currently testing much higher doses of oral semaglutide efficacy specifically for weight loss, as well as new molecules like oral glp-1 tirzepatide. Early data suggests these investigational pills could rival the results of the shots, offering patients the best of both worlds.

The Convenience Factor: Daily vs. Weekly

When choosing between weight loss pills vs shots, lifestyle plays a huge role.

The Case for the Shot:

• Frequency: Once a week. You treat it and forget it for six days.
• Flexibility: You can take it at any time of day, with or without food.

The Case for the Pill:

• Frequency: Daily.
• Strict Adherence: Because absorption is so difficult, current oral GLP-1s typically must be taken on an empty stomach with a small sip of water, at least 30 minutes before eating, drinking, or taking other meds. For some, the "morning fast" ritual is a small price to pay to avoid injections. For others, the weekly shot is actually more convenient than a strict daily routine.

Side Effects: Is the Stomach Discomfort the Same?

The common side effects of GLP-1s are well-known: nausea, vomiting, diarrhea, and constipation.

• GLP-1 side effects tend to be similar across both pills and shots because they are caused by the hormone's effect on the gut and brain, not just the delivery method.
• However, because oral versions are processed through the stomach, some patients report different intensities of GI distress.
• Gradual titration (starting at a low dose and increasing slowly) is the key to managing these symptoms for both forms.

Beyond Weight: Sleep Apnea and Heart Health

The benefits of these medications extend beyond the scale. Losing weight can significantly improve conditions like sleep apnea and hypertension. As we move toward FDA approval for new oral formulations, researchers are also studying how these pills impact cardiovascular outcomes and sleep quality, ensuring that the "pill" version offers the same holistic health protection as the "pen."

Frequently Asked Questions (FAQ)

Q: Are oral GLP-1s as effective as injectables for weight loss? 

A: Currently, approved oral doses (like Rybelsus) are primarily indicated for diabetes and typically result in less weight loss than high-dose injectables like Wegovy or Zepbound. However, investigational clinical trials are testing higher-dose oral versions that show promise in achieving comparable weight loss results.

Q: Can I switch from a weekly injection to a daily pill? 

A: Switching is often possible, but it requires a strategic plan from your doctor to match the dosing equivalents and manage blood sugar levels during the transition. You should never stop one and start the other without medical guidance.

Q: Why do I have to take the pill on an empty stomach? 

A: This is due to "bioavailability." Food and drink can interfere with the absorption technology (often a molecule called SNAC) that helps the drug pass through the stomach wall. Taking it with food would likely render the medication ineffective.

Q: Do these medications replace diet and exercise? 

A: No. Whether you choose a pill or a pen, these drugs are designed to be used in conjunction with physical activity and a healthy diet. They are tools to help you lose weight and maintain it, but they work best when paired with lifestyle changes.

---

Interested in the future of weight management? Science 37 is currently conducting clinical trials for new, investigational oral GLP-1 options. If you are looking for a needle-free alternative, help us advance the science from the comfort of your home. Check Your Eligibility Today

When a child is diagnosed with Lennox-Gastaut Syndrome (LGS), the focus is almost exclusively on the "now." Parents are consumed by managing daily seizures, navigating developmental delays, and fighting for the best pediatric care.

But children with LGS do grow up.

Thanks to advances in medical care, the Lennox-Gastaut life expectancy has improved, meaning more patients are living well into adulthood. However, reaching the age of 18 brings a new, often daunting challenge: the "transition cliff." This is the moment when a patient ages out of the supportive, wraparound world of pediatric neurology and enters the often fragmented system of adult epilepsy care.

For caregivers, this transition requires early planning and a shift in strategy. Here is how to navigate the complex journey of LGS in adulthood.

The Reality of the "Transition Cliff"

Pediatric hospitals are designed to be family-centered. Your child’s neurologist likely knows your family by name, and social workers are often on hand to help with school and therapy.

Adult medicine is different. It focuses on the individual patient, often assuming a level of independence that many LGS patients—who may have significant cognitive impairment—do not possess. When a patient turns 18 years old, privacy laws (like HIPAA) can suddenly shut parents out of medical conversations unless legal structures are in place.

Furthermore, finding an adult neurologist who specializes in complex, rare epilepsy syndromes can be difficult. Many adult providers are accustomed to treating general epilepsy and may have less experience with the specific drug-resistant seizure types and comorbidities associated with LGS.

1. Legal Guardianship and Advocacy

The most critical step in preparing for LGS in adults happens in the courtroom, not the exam room. Before your child turns 18, it is essential to explore guardianship for special needs.

Without legal guardianship or power of attorney, you may lose the legal right to make medical decisions, access health records, or even manage insurance for your child. The process can take months, so experts recommend starting this process around age 16 or 17.

2. Bridging the Gap in Medical Records

In pediatrics, your team likely had a comprehensive view of your child’s history. In the adult system, you are often the keeper of that history.

When transitioning to adult neurology, ensure you have a "transportable" medical package ready. This should include:

• A summary of drug resistance history (which medications failed and why).
• Recent electroencephalogram (EEG) reports and MRI scans.
• A clear list of rescue protocols and seizure action plans.
• Genetic testing results.

Having this data organized prevents the new adult provider from "starting from scratch" or ordering unnecessary repeat tests that can be traumatic for the patient.

3. The Challenge of "Physical" Access

As patients with LGS age, they get bigger and heavier. The physical logistics of care become harder. Lifting a 6-year-old into a car seat for a hospital visit is very different from transporting a 25-year-old adult who may have mobility issues or use a wheelchair.

This physical burden often leads to isolation. Families may stop seeking aggressive treatment or second opinions simply because the travel required to see a specialist is too physically demanding or dangerous. This can result in a decline in quality of life and missed opportunities for better seizure control.

4. The Role of Clinical Trials in Adult Care

For many years, research was heavily skewed toward children. However, science is catching up. There is a growing recognition of the need for clinical trials specifically for adults with LGS.

But how does an adult with mobility challenges and complex medical needs participate in a trial that requires frequent visits?

This is where Science 37 is changing the landscape. Through our Direct-to-Patient Site model, we are bringing clinical practice and research directly to the home.

• Home Visits: Our mobile nurses come to your house to perform blood draws, vitals checks, and assessments.
• Telemedicine: You can consult with the study doctor via video call, eliminating the need to transport your loved one to a clinic.
• Remote Monitoring: We can use digital tools to track seizure activity, offering a more accurate picture of daily life than a 20-minute clinic visit ever could.

By removing the travel barrier, we ensure that adults with LGS are not left behind in the search for better treatments.

Conclusion: A Continuum of Care

Lennox-Gastaut Syndrome does not end at childhood, and neither should the support. While the transition to adult care is a major hurdle, it is navigable with preparation, legal protection, and the right partners.

Whether it is finding a compassionate adult epileptologist or participating in decentralized research, the goal remains the same: helping every person with LGS live their fullest, safest life at every age.

---

Are you caring for an adult with LGS? You may be eligible to participate in cutting-edge clinical research without leaving your home. Science 37 makes it possible to access new potential therapies without the burden of travel. 

View Open Studies

---

Frequently Asked Questions (FAQ)

Q: What is the life expectancy for someone with Lennox-Gastaut Syndrome? 

A: Historically, the prognosis for LGS was considered poor, but medical care has improved significantly. Today, many individuals with LGS live well into their 50s, 60s, and beyond. However, adults with LGS do face a higher mortality risk than the general population, largely due to complications like Sudden Unexpected Death in Epilepsy (SUDEP), accidents from falls (drop attacks), or aspiration pneumonia. Regular monitoring by an adult neurologist is critical for managing these risks.

Q: Do seizure types change as children with LGS become adults? 

A: Yes, the "seizure profile" often evolves. While the types of seizures may change—for example, atypical absence seizures may become less frequent—tonic seizures (stiffening, especially during sleep) and atonic seizures (drop attacks) often persist into adulthood. Because drop attacks continue to pose a high risk for injury, fall safety measures like helmets or wheelchair use often remain necessary.

Q: When should I start the legal guardianship process? 

A: You should begin preparing for guardianship before your child turns 18. In most states, once a child turns 18, they are legally considered an adult, and you may lose access to their medical records and the ability to make healthcare decisions for them due to privacy laws (HIPAA). Experts recommend consulting with a special needs attorney around age 16 or 17 to ensure guardianship or power of attorney is in place by their 18th birthday.

Q: Can adults with LGS live independently? 

A: Most adults with LGS will require some level of lifelong care due to cognitive impairment and ongoing seizures. While independent living is rare, many adults thrive in supported living environments, such as group homes or community-based residential facilities, where they can socialize and receive assistance with daily tasks.

Q: Is it harder to find a doctor for LGS in the adult healthcare system? 

A: It can be. Pediatric neurologists often have more specific training in rare epilepsy syndromes than general adult neurologists. When transitioning, look for an epileptologist (a neurologist who specializes in epilepsy) rather than a general practitioner. Participating in decentralized clinical trials (like those at Science 37) can also help bridge this gap by providing access to specialized oversight without requiring travel to distant specialty centers.

If you are a caregiver for a child with Dravet syndrome, your daily life likely revolves around one major concern: seizures. From the first terrifying instance of Febrile seizures in infancy to the complex management of epilepsy in childhood, seizure control takes center stage.

But for many families, the seizures are just the tip of the iceberg.

Dravet syndrome, typically caused by a mutation in the SCN1A gene, is a complex "channelopathy." This means the genetic variance affects sodium channels throughout the entire body, not just in the brain areas responsible for epilepsy. As a result, parents often notice a constellation of other challenges that don't always get the same attention in the doctor’s office.

These "invisible" symptoms, or comorbidities of epilepsy can impact a family's quality of life just as much as the seizures themselves. Understanding them is the first step toward better management and finding the right support.

Here are five lesser-known symptoms of Dravet syndrome that you should know about, and how modern research studies are working to address them.

1. Behavioral and Emotional Regulation Challenges

One of the most difficult aspects of Dravet syndrome for families to navigate is behavior. It is common for children with Dravet to exhibit traits often associated with Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD).

Dravet syndrome behavior can present as hyperactivity, impulsivity, or difficulty with social interactions. You might notice sudden mood swings or outbursts that seem disproportionate to the situation. These aren't just "acting out"; they are often neurological manifestations of the condition itself.

Because the SCN1A non-seizure symptoms affect how the brain processes information, children may struggle to regulate their emotions. Recognizing this as a symptom rather than "bad behavior" can help caregivers approach discipline and support with new strategies, and help educators understand the unique needs of the child.

2. Chronic Sleep Disturbances

Sleep is precious for any parent, but for Dravet families, it is often elusive. Sleep problems in Dravet syndrome are widely reported but frequently undertreated.

The issues can range from difficulty falling asleep (insomnia) to frequent night wakings or disjointed sleep cycles. This is particularly stressful because sleep deprivation can lower the seizure threshold, creating a vicious cycle where poor sleep leads to more seizures, and more seizures lead to poorer sleep.

Research suggests that the circadian rhythms in Dravet patients may be disrupted at a genetic level. Addressing sleep hygiene is crucial, and it’s a key area that new clinical trials are beginning to monitor more closely as a measure of a treatment's success.

3. Gait and Balance Issues

As children with Dravet syndrome grow, parents often notice changes in how they walk. Dravet syndrome gait is a specific movement pattern often characterized by a crouched walk or a slightly wide-based stance.

You might observe balance issues or clumsiness (ataxia) that seems to worsen when the child is tired or recovering from a seizure. This is due to the impact of the condition on the cerebellum, the part of the brain responsible for coordination.

Physical therapy is often a "do" in the list of do’s and don’ts for Dravet management. Strengthening core muscles can help improve stability and safety, reducing the risk of falls during daily activities.

4. Temperature Dysregulation

The hallmark of Dravet onset is often heat sensitivity. Most parents are painfully aware that a warm bath, a hot summer day, or a fever can trigger a seizure. However, the issue with body temperature goes beyond just being a seizure trigger; it is a symptom of autonomic dysfunction.

Children with Dravet may have trouble regulating their own body temperature. They might not sweat efficiently to cool down, or they might experience rapid fluctuations in temperature that have nothing to do with infection. This autonomic instability requires constant vigilance, especially during physical activity or seasonal changes.

5. Developmental Delays and Cognitive Stagnation

While development in the first year of life is often typical, developmental delays usually become apparent in the second or third year. This "slowing down" of cognitive progress can be heartbreaking for parents to witness.

It is important to understand that this is a feature of the syndrome, not a failure of parenting or education. The cognitive plateau is often linked to the frequency of seizures, but researchers now believe the underlying gene mutation plays a direct role in cognitive development as well.

Early intervention therapies (speech, occupational, and physical) are critical. Furthermore, many families explore dietary therapies, such as the ketogenic diet, which has been shown to support cognitive alertness in some children by altering the brain's energy metabolism.

How Clinical Research is shifting the Focus

Historically, success in epilepsy trials was measured by one metric: did the seizure count go down? While that remains the gold standard, the definition of success is evolving.

Sponsors and researchers in clinical trials, including those conducted through the Science 37 Direct-to-Patient Site are increasingly measuring "Quality of Life" (QoL) endpoints. We are asking: Is the patient sleeping better? Is their behavior stabilizing? Are they walking with more confidence?

Because Science 37 brings the trial to your home, we are uniquely positioned to capture this data. Our mobile nurses can see how a patient moves in their own living room, not just in a sterile clinic hallway. This "real-world" data helps drug developers create treatments that address the whole child, not just the seizures.

Frequently Asked Questions (FAQ)

Q: Is genetic testing necessary if my child already has a clinical diagnosis of Dravet? 

A: Yes, genetic testing is highly recommended. Confirming the SCN1A mutation (or other associated genes) not only solidifies the diagnosis but can also guide treatment choices. Certain common epilepsy medications (sodium channel blockers) can actually worsen Dravet syndrome, so knowing the genetics is a critical safety step.

Q: Can the ketogenic diet replace medication for Dravet syndrome? 

A: The ketogenic diet is a powerful tool and is often used alongside medication, but it rarely replaces it entirely. It is considered a medical therapy and should only be attempted under the strict supervision of a neurologist and a dietitian to ensure the child gets adequate nutrition while maintaining ketosis.

Q: Will my child outgrow the behavioral challenges associated with Dravet? 

A: Dravet syndrome behavior tends to evolve rather than disappear. While some hyperactivity may decrease with age, other issues like executive function deficits or social difficulties may persist. Consistent behavioral therapy and a supportive educational environment are key to managing these symptoms long-term.

Q: How can I find research studies that focus on non-seizure symptoms? 

A: Many modern research studies are now including secondary endpoints that look at sleep, behavior, and cognition. When evaluating clinical trials, ask the study team what "scales" or "assessments" are being used. Trials that use Quality of Life questionnaires or sleep logs are likely gathering data on these important comorbidities.

---

Are you caring for a loved one with Dravet Syndrome? Science 37 is currently conducting research studies that prioritize patient comfort and family convenience. By bringing the study to your home, we make participation possible for families who cannot travel. 

Check our Open Studies to see if a trial is right for you.

Epilepsy is never simple, but Lennox-Gastaut Syndrome (LGS) represents one of the most complex and difficult mountains to climb in the landscape of neurological disorders.

Emerging typically in early childhood (between ages 3 and 5), LGS is a rare and severe childhood epilepsy characterized by multiple types of seizures and cognitive challenges. Unlike some pediatric syndromes that children "outgrow," the journey of LGS often persists well into adulthood, requiring a lifetime of care, advocacy, and adaptation.

For families, the diagnosis brings a heavy realization: this is likely drug-resistant epilepsy. But while the diagnosis is tough, the community is tougher. By understanding the unique seizure landscape, prioritizing safety, and engaging with new research, families can navigate the transition from diagnosis to daily management and eventual transition to adult care.

The Reality of "Drop Attacks" and Seizure Types

LGS is defined by its volatility. Children and adults with LGS don’t just experience one type of seizure; they experience a mix, often on a daily basis.

The most distinguishing (and dangerous) feature of LGS is the presence of atonic seizures, commonly known as "drop attacks." During these episodes, the body suddenly loses all muscle tone. If the person is standing, they collapse instantly, leading to a high risk of head injury or broken bones.

Other common types include:

• Tonic Seizures: The body suddenly stiffens. These often happen during sleep.
• Atypical Absence Seizures: A staring spell where the person is unresponsive.
• Myoclonic Seizures: Brief, shock-like jerks of a muscle or group of muscles.

Because these seizures often occur in seizure clusters, the physical toll on the patient is immense.

The Challenge of Treatment Resistance

One of the hardest conversations a doctor has with an LGS family is explaining that standard anti seizure medications may not work. LGS is notoriously resistant to treatment.

While magnetic resonance imaging (MRI) is used to rule out brain lesions or tumors, it often comes back normal in LGS patients, meaning there is no single "spot" in the brain to operate on. However, for some, epilepsy surgery (like corpus callosotomy) can help reduce drop attacks.

When medications fail, families often turn to palliative treatments to improve quality of life:

• Vagus Nerve Stimulation (VNS): VNS therapy involves a device implanted under the skin that sends electrical impulses to the brain to inhibit seizures.
• Dietary Therapies: The Ketogenic diet.
• New Pharmacotherapy: Research is constant, looking for new drug classes that can bypass the resistance mechanisms in LGS brains.

This difficulty in treatment is exactly why clinical trials for LGS are so critical. We are still searching for the key that unlocks better control for this specific community.

Safety First: Do’s and Don’ts at Home

When living with drop attacks and cognitive impairment, safety becomes a lifestyle. Here is a practical guide for setting up a safe environment.

The Do’s

• Do use protective gear: A well-fitted medical helmet is non-negotiable for those with frequent drop attacks to prevent traumatic brain injury.
• Do "seizure-proof" the home: Pad sharp corners on furniture and use thick carpeting or foam mats in play areas and bedrooms.
• Do use technology: Wearable seizure monitors and bed alarms can alert caregivers to night-time seizures (tonic seizures) that might otherwise go unnoticed.
• Do have a rescue plan: Always have rescue medications on hand for seizure clusters.

The Don’ts

• Don’t rely on "outgrowing it": LGS persists. Plan for the long term, including financial and legal planning for adulthood.
• Don’t ignore shifts in behavior: In patients with intellectual disability, behavior is communication. Increased aggression or withdrawal can signal a change in seizure activity or medication side effects.
• Don’t swim or bathe alone: Water safety is critical. Showers are generally safer than baths, and supervision is always required.

The Role of Decentralized Research

For a person with LGS, routine is everything. Stress, lack of sleep, and changes in environment are major triggers for seizures. This presents a catch-22: LGS treatment options need to improve through research, but participating in traditional clinical trials (which require travel and long hospital visits) can trigger the very seizures families are trying to stop.

This is why decentralized clinical trials are a beacon of hope for the LGS community.

By bringing the trial to the patient, using mobile nursing units, telehealth, and home delivery of study medications, we remove the disruption.

• Less Travel: No long car rides or flights that disrupt sleep schedules.
• Home Comfort: Assessments happen in the patient’s safe, padded, familiar environment.

Real-World Data: Researchers get to see how the treatment works in real life, not just in a sterile clinic.

Finding Hope in Community

Living with LGS is a marathon, not a sprint. While the family history of epilepsy is rare in LGS (it usually appears sporadically), the family future is one of resilience.

Connecting with family resources for epilepsy, such as the LGS Foundation, reminds you that you aren't navigating this alone. And by exploring research opportunities, you are actively helping to rewrite the future of this condition.

Frequently Asked Questions About LGS

1. Does LGS affect intelligence? 

Yes, most individuals with Lennox-Gastaut Syndrome experience some degree of intellectual disability or cognitive impairment. This is often due to the combined effect of the underlying brain cause and the frequent, uncontrolled electrical activity during critical periods of development.

2. Is LGS genetic? 

In many cases, the cause is unknown (idiopathic). However, it can result from brain malformations, lack of oxygen at birth, or severe brain infections. A family history of epilepsy is actually less common in LGS than in other epilepsy syndromes, though genetic research is ongoing.

3. What is the difference between a drop attack and a faint? 

Atonic seizures (drop attacks) are sudden and forceful. The person doesn't slowly "swoon" like in a faint; they are thrown to the ground as if their strings were cut. Recovery is usually immediate, whereas someone who faints may be groggy or confused for a while.

4. How do I transition my child to adult care? 

Transition to adult care is a major hurdle in LGS. It requires early planning (starting around age 14) to transfer medical records, establish legal guardianship if necessary, and find an adult neurologist familiar with severe childhood epilepsy syndromes that persist into adulthood.

---

Discover active clinical trials for Lennox-Gastaut Syndrome.

For most people, epilepsy is a condition characterized by occasional seizures that, with the right medication, can often be managed. But for the parents of a child with Dravet Syndrome, the reality is vastly different.

Dravet Syndrome is not just "epilepsy." It is a rare, catastrophic form of genetic epilepsy that begins in infancy. It is resistant to many standard treatments and comes with a unique set of developmental challenges.

If you are a parent or caregiver navigating a recent diagnosis, you likely feel overwhelmed by medical terminology and the sudden shift in your family’s life. Understanding the specific nature of this condition, from the SCN1A gene to the unique seizure triggers is the first step in advocacy. While the journey is difficult, advancements in rare disease research and participating in rare disease trials are opening new doors for families who need them most.

Beyond Standard Epilepsy: What is Dravet Syndrome?

Dravet Syndrome is a rare epilepsy in children that typically presents in the first year of life. Unlike other forms of epilepsy that might develop later or result from injury, Dravet is genetic.

Approximately 80% of cases are caused by a mutation in the SCN1A gene. This gene is responsible for the function of sodium channels in the brain, which control how brain cells communicate. When this gene mutates, the brain’s "brakes" fail to work properly, leading to unchecked electrical activity.

The condition often starts with febrile seizures, which are seizures triggered by a fever or a spike in body temperature. While febrile seizures can happen in healthy children, in Dravet Syndrome, they are prolonged, frequent, and evolve into other seizure types over time.

Understanding the Unique Triggers and Symptoms

One of the most terrifying aspects of Dravet Syndrome is the unpredictability. Dravet syndrome symptoms vary, but the sensitivity to environmental changes sets it apart from other epilepsies.

Caregivers must become experts in managing an environment that most people take for granted. Common seizure triggers include:

• Body Temperature Changes: A hot bath, a warm summer day, or even physical exertion can trigger a seizure.
• Photosensitivity: Flashing lights or distinct visual patterns.
• Illness: Even a mild cold can escalate quickly due to fever.
• Emotional Stress: Excitement or anxiety.

Because status epilepticus (a seizure lasting longer than 5 minutes or seizures occurring close together without recovery) is a significant risk, parents often live in a state of high alert.

The "Around-the-Clock" Reality of Caregiving

Caring for a child with Dravet Syndrome is a 24/7 job. It is not just about administering antiseizure medication; it is about constant surveillance.

The quality of life for caregivers is often severely impacted. You may find yourself sleeping with one eye open, monitoring monitors, or dreading the next illness. The fear of Sudden Unexpected Death in Epilepsy (SUDEP) is a heavy, silent burden that many parents carry.

We want to validate that toll. The emotional and physical exhaustion you feel is real. You are acting as a nurse, advocate, and protector, often at the expense of your own rest and well-being. This is why caregiver support is not a luxury, it is a medical necessity. Finding a community, whether online or locally, can provide a lifeline of understanding that friends and family outside the rare disease community may not offer.

The Role of Research and Decentralized Trials

For conditions like Dravet Syndrome, existing treatments often fall short. While some children find relief through a ketogenic diet for epilepsy or specific medications, many remain drug-resistant. This makes clinical research vital.

However, traditional clinical trials have historically been out of reach for Dravet families. Why? Because traveling with a seizure-prone child is dangerous. Disruption to routine, the stress of travel, and exposure to germs in hospital waiting rooms are all major seizure triggers.

This is where decentralized clinical trials are changing the landscape of pediatric neurology.

Organizations like Science 37 are bringing the trial phase directly to the patient's home. By utilizing telehealth, mobile healthcare providers, and remote monitoring, families can participate in groundbreaking research without dragging a vulnerable child to a distant research center.

• Safety: Your child remains in their controlled, safe environment.
• Access: You can access specialists and new therapies regardless of where you live.
• Reduced Burden: We handle the logistics, allowing you to focus on caring for your child.

Moving Forward with Hope

A diagnosis of Dravet Syndrome changes everything, but you are not alone in this journey. The landscape of rare disease research is moving faster than ever before. New therapies targeting the root genetic causes are being explored, and clinical trials are becoming more accessible to the families who need them most.

By prioritizing your child's safety and your own mental health, and by staying informed about new research opportunities, you are doing everything possible to provide the best life for your child.

Frequently Asked Questions About Dravet Syndrome

1. Is Dravet Syndrome hereditary? 

While Dravet is a genetic epilepsy caused often by the SCN1A gene, it is usually not inherited from the parents. In most cases, the mutation is "de novo," meaning it occurs spontaneously in the child. However, genetic testing is essential to confirm the diagnosis and understand the specific mutation, which can guide treatment choices.

2. Can diet really help control seizures? 

Yes. The ketogenic diet (a high-fat, low-carbohydrate diet) has been shown to be effective in reducing seizures for some children with Dravet Syndrome who do not respond well to medication. It is a strict medical therapy that should only be attempted under the supervision of a dietician and neurologist.

3. What is the long-term outlook for children with Dravet Syndrome? 

Dravet Syndrome is a lifelong condition associated with developmental delays, speech issues, and mobility challenges that often become more apparent in the second or third year of life. While there is no cure yet, early intervention and management of seizures can help maximize a child's developmental potential and quality of life.

4. Why is participation in clinical trials important? 

Because Dravet is a rare disease, the patient population is small. Every participant in a study provides critical data that helps researchers understand the condition and develop better treatments. With decentralized trials, participating in rare disease trials is now safer and more feasible for families, ensuring that long term solutions can be found faster.

See how you can participate in Dravet research from home.

January is here, and with it comes the annual tidal wave of "New Year, New Me" messaging. Gym memberships skyrocket, grocery stores push kale smoothies to the front of the aisle, and millions of people set out with the best intentions to overhaul their health. But for the millions of Americans living with obesity, this time of year can feel less like a fresh start and more like a recurring cycle of frustration.

For decades, society has framed obesity management as a simple equation: eat less, move more. The implication is that if you aren't seeing results, you simply aren't trying hard enough. But medical science tells a very different story.

Obesity is not a failure of character; it is a complex, chronic disease. It is influenced by a web of factors including genetic factors in obesity, environmental triggers, and powerful biological mechanisms that often fight against weight loss. By understanding the science behind the condition, we can reduce the stigma, embrace patient-centric care, and explore new paths to long-term health.

The Biology of Weight: Why It’s Not Just "Calories In, Calories Out"

To understand why weight management is so difficult, we have to look inside the body’s operating system. Your body is biologically wired to survive, and for most of human history, survival meant holding onto energy (fat) to withstand famine.

When you reduce your calorie intake, your body doesn't just sit back and let the weight drop. It often perceives this as a threat. In response, it triggers a cascade of physiological changes designed to conserve energy and regain the lost weight. This is known as metabolic adaptation.

The Role of Hormonal Imbalance

Your appetite and metabolism are regulated by a complex system of hormones. When you have obesity, these signals can become disrupted.

• Leptin Resistance: Leptin is the hormone that tells your brain, "I'm full, we have enough energy stored." In many people with obesity, the brain stops responding to leptin signals, meaning the feeling of fullness doesn't trigger as it should.
• Ghrelin: Known as the "hunger hormone," ghrelin levels can spike when you begin a diet, increasing cravings and making adherence to healthy foods incredibly difficult.
• Insulin: High levels of insulin, often associated with insulin resistance, can promote fat storage rather than fat burning.

This hormonal imbalance means that for many, the drive to eat is not a lack of willpower, it is a powerful biological imperative.

The Gut-Brain Connection

Your digestive system does more than break down food; it communicates constantly with your brain. Changes in the gut microbiome (the trillions of bacteria living in your digestive tract) can influence how you store fat, how you respond to insulin, and even how much you crave sugar. This is why metabolic health is about so much more than the number on the scale.

The Health Impact: Looking Beyond the Mirror

While the social conversation around obesity often focuses on aesthetics, the medical conversation focuses on longevity and quality of life. Obesity is a systemic disease that affects nearly every organ in the body.

Carrying excess adipose tissue (body fat) creates a state of chronic low-grade inflammation. Over time, this can lead to serious comorbidities of obesity, including:

• High Blood Pressure: Excess weight forces the heart to work harder to pump blood, straining the arteries.
• Heart Disease: Inflammation and cholesterol levels associated with obesity significantly increase the risk of cardiovascular events.
• Type 2 Diabetes: As we’ve discussed in our other diabetes awareness posts, obesity is a primary risk factor for developing insulin resistance.
• Joint Issues: The physical stress on joints can lead to osteoarthritis and reduced mobility.

Understanding these risks highlights why chronic disease management is so important. It isn’t about fitting into a certain dress size; it’s about protecting your heart, your brain, and your future.

Breaking the Stigma Barrier

One of the biggest hurdles in obesity management is stigma. People with obesity often face bias in the workplace, in social settings, and even in healthcare offices. This "weight bias" can lead to a vicious cycle. Patients may feel judged by their doctors, leading them to delay or avoid necessary medical care.

Reducing stigma starts with changing the language. Recognizing obesity as a disease rather than a lifestyle choice validates the patient's experience. It shifts the focus from "blame" to "treatment." Just as we wouldn't shame someone for having asthma or hypertension, we should not shame someone for having obesity.

Modern Treatment: A Toolkit, Not a Silver Bullet

Because the causes of obesity are multifaceted, the treatment must be too. Successful management often requires a combination of strategies.

1. Lifestyle Foundations

While biology plays a huge role, lifestyle is still the foundation of health. This includes:

• Healthy Foods: Prioritizing nutrient-dense, whole foods that support metabolic health without triggering extreme blood sugar spikes.
• Physical Activity: Exercise is vital for heart health and maintaining muscle mass. Muscle is metabolically active tissue, meaning it burns more calories at rest than fat does. Preserving muscle during weight loss is crucial for long-term maintenance.
• Sleep: Poor sleep disrupts hunger hormones and can sabotage your weight loss efforts.

2. Medical Interventions

For many, lifestyle changes alone aren’t enough to overcome the body’s biological resistance to weight loss. This is where medical science steps in.

• Pharmacotherapy: There are several obesity treatment options approved by the Food and Drug Administration (FDA). New classes of medications, such as GLP-1 agonists, mimic natural hormones to help regulate appetite and blood sugar.
• Bariatric Surgery: For severe cases, surgical interventions can alter the digestive system to limit food intake and change hormonal signals.

3. The Future of Care: Clinical Trials

Despite recent advancements, we still have a long way to go in understanding how to treat obesity effectively for everyone. What works for one person may not work for another. This is why weight loss research is critical.

The Role of Decentralized Clinical Trials

Historically, participating in obesity research was burdensome. It required frequent travel to clinics, uncomfortable weigh-ins in public waiting rooms, and disruptions to daily life. For individuals with mobility issues or those who fear judgment in clinical settings, these barriers often prevent participation.

This is where Science 37 is changing the landscape. Through telehealth for weight management research, we bring the trial to you.

Clinical trials for weight loss conducted via the decentralized model allow you to participate from the privacy of your own home.

• Privacy: Consultations happen via secure video calls, removing the anxiety of the waiting room.
• Convenience: Data regarding your physical activity, weight, and vital signs can often be collected via wearable devices and digital tools.
• Inclusivity: By removing the travel requirement, we make it easier for people of all backgrounds and locations to contribute to science.

Taking the Next Step

If you are navigating the complexities of obesity, know that you are not alone, and it is not your fault. Science is moving fast, and we are uncovering new ways to support metabolic health every day.

Whether through healthy lifestyle changes, seeking medical support, or participating in research, taking action is an act of self-care. If you are interested in accessing potential new therapies and contributing to the next generation of obesity treatment options, consider joining a clinical trial.

Together, we can move beyond willpower and toward a future of health, empathy, and effective science.

Frequently Asked Questions About Obesity Management

1. Is obesity purely genetic? 

While genetics are not the sole cause, genetic factors in obesity play a significant role (estimated between 40-70%). Your genes can influence your appetite, metabolism, and how your body stores fat. However, genetics are a contributor, and environmental factors (like food availability and activity levels) all play their parts as well.

2. Why is BMI used if it’s not perfect?

BMI and health are often linked in medical discussions, but BMI (Body Mass Index) is a screening tool, not a diagnostic one. It provides a quick estimate of body fat based on height and weight but does not account for muscle mass, bone density, or fat distribution. Doctors should use it alongside other metrics like waist circumference and blood pressure for a full picture.

3. Why do I gain weight back after dieting? 

This is often due to metabolic adaptation. When you lose weight, your body may lower its metabolic rate and increase hunger hormones to try to return to its previous "set point." This makes long-term weight management challenging and often requires sustainable lifestyle changes or medical treatment to maintain.

4. Are clinical trials for weight loss safe? 

All clinical trials in the U.S. must be reviewed by the Food and Drug Administration (FDA) and an Institutional Review Board (IRB) to ensure patient safety. While there are risks with any medical study, trials are closely monitored by medical professionals. Participating in a decentralized trial with Science 37 ensures you have continuous support and monitoring from home.

View current studies advancing metabolic health.

For most families, hunger is a natural part of daily life - a signal that comes and goes. But for people living with Prader-Willi Syndrome (PWS), that signal doesn’t function in the same way. Hunger can feel persistent and difficult to manage, creating challenges that touch nearly every part of daily life. Clinical research is working to better understand these experiences and develop treatments that can truly support individuals and families affected by PWS.

PWS is a rare and complex genetic disorder that occurs in approximately one in every 15,000 to 25,000 births. It affects growth, metabolism, behavior, and appetite, creating a unique set of challenges that evolve as a child grows into adulthood.

Navigating a diagnosis of PWS often feels like learning a new language. There are medical terms to master, strict routines to establish, and a lifetime of vigilance required to ensure safety. However, the landscape of PWS research is shifting. New understanding of the hypothalamus gland and the expansion of decentralized clinical trials are bringing hope to a community that has long waited for more safe and effective treatment options.

Defining the Condition: More Than Just Hunger

To understand PWS, we must look at the biology behind it. The condition is caused by an abnormality on chromosome 15, which disrupts the normal function of the hypothalamus gland. This small part of the brain acts as the body's control center, regulating hormones, sleep, and, crucially, appetite.

When the hypothalamus malfunctions, it sets off a cascade of symptoms that change over time.

The Dual-Phase Nutritional Challenge

One of the most confusing aspects of PWS for new parents is the drastic shift in symptoms during childhood.

• Phase 1: Failure to Thrive. In infancy, babies with PWS typically have weak muscle tone, known as hypotonia. This makes feeding difficult, often leading to slow growth and a "failure to thrive" diagnosis.
• Phase 2: Hyperphagia. Somewhere between the ages of 2 and 8, the switch flips. The child develops hyperphagia, which causes an intense, insatiable hunger. This is not just "liking food"; it is a physiological drive so powerful that it overrides satiety signals. Without strict environmental controls, this can lead to life-threatening obesity and complications.

Beyond the Physical: Behavioral and Neurological Impacts

While hunger is the most well-known symptom, the behavioral challenges can be just as difficult for caregivers to manage. Many individuals with PWS experience high levels of anxiety, obsessive-compulsive tendencies, and extreme rigidity regarding routines. A sudden change in schedule can trigger a meltdown, not out of stubbornness, but out of an inability to process the shift.

Additionally, many individuals face intellectual disability or learning delays, requiring specialized educational support. Later in life, hypotonia in adults (low muscle tone) continues to affect stamina and physical strength, while sleep disturbances like sleep apnea can exacerbate behavioral issues by causing chronic fatigue.

The Current Standard of Care and Its Limits

Currently, there is no cure for Prader-Willi Syndrome. Treatment focuses on managing symptoms to improve quality of life.

• Growth Hormone Treatment: This is a cornerstone of care for many children with PWS. It helps improve height, increase muscle mass, and decrease body fat, which can help counteract some of the physical limitations caused by the disorder.
• Strict Environmental Control: Families often have to lock pantries and refrigerators to prevent unauthorized eating.
• Behavioral Therapy: Strategies to manage anxiety and rigidity are essential for daily functioning.

While these interventions help, they do not address the root cause of the hunger or the underlying hypothalamic dysfunction. This is why rare disease research is so critical.

How Research is changing the Narrative

The goal of modern PWS research is to move beyond symptom management and target the underlying biological mechanisms. Scientists are currently conducting research studies to understand exactly how the brain signals hunger and satiety in PWS patients.

New potential therapies are being tested to see if they can silence the "hunger noise" in the brain. However, developing these treatments requires rigorous testing to ensure they are safe and effective. This process involves multiple phases of clinical trials, oversight by an ethics committee, and careful monitoring for side effects.

For a long time, the barrier to these trials wasn't just the science, it was the logistics.

The Decentralized Advantage for PWS Families

Participating in a clinical trial used to mean frequent travel to a major research hospital. For a family managing PWS, this is often impossible.

• Disruption of Routine: Travel disrupts the strict schedules that people with PWS rely on for emotional stability, often leading to severe behavioral outbursts.
• Food Security: Navigating airports, hotels, and new cities presents constant food access challenges, increasing anxiety for both the patient and the caregiver.

Decentralized clinical trials (DCTs) are solving this problem by bringing clinical trial participation directly to the patient’s home.

Through Science 37’s operating system, families can participate in groundbreaking research without leaving their safe, controlled environments.

• Telehealth visits replace long drives to the clinic.
• Mobile nurses come to the home to perform blood draws or physical checks.
• Wearable devices monitor sleep and activity levels in the real world, providing researchers with better data on how PWS affects daily life.

This model opens the door for clinical trial participation to families who previously could never consider it, ensuring that new treatments are tested on a diverse, representative group of patients.

Frequently Asked Questions About PWS Research

Q: What causes the uncontrollable hunger in PWS? 

A: Hyperphagia causes are rooted in the dysfunction of the hypothalamus gland. The brain fails to receive or process the signal that the stomach is full, leaving the individual in a state of constant, starving hunger, regardless of how much they have eaten.

Q: Are clinical trials safe for someone with PWS? 

A: Patient safety is the top priority in any study. Every trial is reviewed by an independent ethics committee to protect participants' rights and well-being. Researchers also closely monitor for side effects and have strict protocols in place to manage the unique dietary and behavioral needs of PWS patients.

Q: Can adults with PWS participate in research? 

A: Yes. While much focus is placed on children, hypotonia in adults and long-term complications like sleep disturbances are major areas of interest. Research is essential for improving the quality of life for the adult PWS community.

Q: How do I find out if there is a study for us? 

A: You can look for active research studies through patient advocacy groups or by visiting research platforms like Science 37. Our team can help determine if you or your loved one meets the specific criteria for current trials.

A Future Defined by Hope

Living with Prader-Willi Syndrome is a journey of resilience. It requires a family to be vigilant, structured, and endlessly patient. But you do not have to walk this path alone.

By participating in rare disease research, you are helping to rewrite the story of PWS. You are contributing to a future where hunger doesn't control life, where anxiety is manageable, and where independence is possible.

If you are ready to be part of the solution, we invite you to explore the possibilities of at-home research today.

[View open clinical trials for rare diseases at Science 37]